Association of serum soluble Receptor for Advanced Glycation End-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS)

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 192-198

  Hudson, Barry I ^a,b   Moon, Yeseon Park ^c   Kalea, Anastasia Z ^a   Khatri, Minesh ^c   Marquez, Chensy ^a   Schmidt, Ann Marie ^a   Paik, Myunghee C ^c   Yoshita, Mitsuhiro ^e   Sacco, Ralph L ^b   DeCarli, Charles ^d   Wright, Clinton B ^b   Elkind, Mitchell S V ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of California Davis ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Biological marker; Hispanics; MRI; RAGE (Receptor for Advanced Glycation End products); Subclinical infarct; White matter hyperintensities

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; ETHNIC DIFFERENCE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AFRICAN AMERICANS; AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BRAIN; CEREBROVASCULAR DISORDERS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; NEW YORK CITY; ODDS RATIO; PREVALENCE; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS;

EID: 79955537037     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.024     Document Type: Article

References (42)

1. Kalea A.Z., Schmidt A.M., Hudson B.I. AGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009, 116:621-637.
2. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
3. Muhammad S., Barakat W., Stoyanov S., et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031.
4. Hudson B.I., Carter A.M., Harja E., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008, 22:1572-1580.
5. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
6. Geroldi D., Falcone C., Emanuele E., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005, 23:1725-1729.
7. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
8. Katakami N., Matsuhisa M., Kaneto H., et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009, 204:288-292.
9. Santilli F., Bucciarelli L., Noto D., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radical Biol Med 2007, 43:1255-1262.
10. Emanuele E., D'Angelo A., Tomaino C., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005, 62:1734-1736.
11. Yilmaz Y., Ulukaya E., Gul O.O., et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009, 42:802-807.
12. Basta G., Sironi A.M., Lazzerini G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
13. Geroldi D., Falcone C., Minoretti P., et al. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 2006, 54:1149-1150.
14. Montaner J., Perea-Gainza M., Delgado P., et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008, 39:2280-2287.
15. Yokota C., Minematsu K., Tomii Y., et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009, 287:41-44.
16. Park H.Y., Yun K.H., Park D.S. Levels of soluble receptor for advanced glycation end products in acute ischemic stroke without a source of cardioembolism. J Clin Neurol 2009, 5:126-132.
17. Vernooij M.W., Ikram M.A., Tanghe H.L., et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007, 357:1821-1828.
18. Vermeer S.E., Hollander M., van Dijk E.J., et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003, 34:1126-1129.
19. Vermeer S.E., Longstreth W.T., Koudstaal P.J. Silent brain infarcts: a systematic review. Lancet Neurol 2007, 6:611-619.
20. Sacco R.L., Benson R.T., Kargman D.E., et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001, 285:2729-2735.
21. Nickolas T.L., Khatri M., Boden-Albala B., et al. The association between kidney disease and cardiovascular risk in a multiethnic cohort: findings from the Northern Manhattan Study (NOMAS). Stroke 2008, 39:2876-2879.
22. Wright C.B., Moon Y., Paik M.C., et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009, 40:3466-3471.
23. DeCarli C., Murphy D.G., Tranh M., et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995, 45:2077-2084.
24. DeCarli C., Maisog J., Murphy D.G., et al. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr 1992, 16:274-284.
25. DeCarli C., Murphy D.G., Teichberg D., et al. Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity. J Magn Reson Imaging 1996, 6:519-528.
26. DeCarli C., Miller B.L., Swan G.E., et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999, 30:529-536.
27. Au R., Massaro J.M., Wolf P.A., et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol 2006, 63:246-250.
28. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
29. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993, 143:1699-1712.
30. Lindsey J.B., de Lemos J.A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009, 32:1218-1220.
31. Allison M.A., Budoff M.J., Wong N.D., et al. Prevalence of and risk factors for subclinical cardiovascular disease in selected US Hispanic ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2008, 167:962-969.
32. Gaens K.H., Ferreira I., van der Kallen C.J., et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009, 94:5174-5180.
33. Abdel-Azeez H.A., El-Okely A.M. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt J Immunol 2009, 16:95-106.
34. Jang Y., Kim J.Y., Kang S.M., et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and non obese Koreans. Metabolism 2007, 56:199-205.
35. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007, 13:185-189.
36. Yamagishi S., Adachi H., Nakamura K., et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55:1227-1231.
37. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
38. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005, 28:2716-2721.
39. Katakami N., Matsuhisa M., Kaneto H., et al. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007, 190:22-23.
40. Choi K.M., Yoo H.J., Kim H.Y., et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009, 132:96-101.
41. Katakami N., Matsuhisa M., Kaneto H., et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes Vasc Dis Res 2008, 5:190-197.
42. Jeerakathil T., Wolf P.A., Beiser A., et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004, 35:1857-1861.